Stock Track | Ardelyx Soars 14.37% After Hours on Strong Q3 Results and Raised Guidance

Stock Track

Oct 31, 2025

Shares of Ardelyx (NASDAQ: ARDX) jumped 14.37% in after-hours trading on Thursday following the release of the company's third-quarter 2025 financial results and corporate update. The biopharmaceutical company reported strong revenue growth and raised its full-year guidance for its lead product, IBSRELA.

Ardelyx reported total revenue of $110.3 million for the quarter, a 12.3% increase compared to the same period last year. The company's flagship product, IBSRELA, generated $78.2 million in revenue, representing a substantial 92% year-over-year growth. This impressive performance led Ardelyx to raise its full-year 2025 revenue guidance for IBSRELA to between $270 and $275 million.

While the company reported a net loss of $969,000 for the quarter, investors appear to be focusing on the robust revenue growth and positive outlook. Ardelyx also announced progress on its pipeline, including the development of RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas. The company plans to file an Investigational New Drug (IND) application for RDX10531 in 2026, further bolstering its future prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1189182471"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189182471\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189182471?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 04:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189182471","market":"hk","top_or_hot":-1,"title":"Stock Track | Ardelyx Soars 14.37% After Hours on Strong Q3 Results and Raised Guidance","media":"Stock Track","content":"<p>Shares of Ardelyx (NASDAQ: ARDX) jumped 14.37% in after-hours trading on Thursday following the release of the company's third-quarter 2025 financial results and corporate update. The biopharmaceutical company reported strong revenue growth and raised its full-year guidance for its lead product, IBSRELA.</p>\n\n<p>Ardelyx reported total revenue of $110.3 million for the quarter, a 12.3% increase compared to the same period last year. The company's flagship product, IBSRELA, generated $78.2 million in revenue, representing a substantial 92% year-over-year growth. This impressive performance led Ardelyx to raise its full-year 2025 revenue guidance for IBSRELA to between $270 and $275 million.</p>\n\n<p>While the company reported a net loss of $969,000 for the quarter, investors appear to be focusing on the robust revenue growth and positive outlook. Ardelyx also announced progress on its pipeline, including the development of RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas. The company plans to file an Investigational New Drug (IND) application for RDX10531 in 2026, further bolstering its future prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ardelyx Soars 14.37% After Hours on Strong Q3 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ardelyx Soars 14.37% After Hours on Strong Q3 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-31 04:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Ardelyx (NASDAQ: ARDX) jumped 14.37% in after-hours trading on Thursday following the release of the company's third-quarter 2025 financial results and corporate update. The biopharmaceutical company reported strong revenue growth and raised its full-year guidance for its lead product, IBSRELA.</p>\n\n<p>Ardelyx reported total revenue of $110.3 million for the quarter, a 12.3% increase compared to the same period last year. The company's flagship product, IBSRELA, generated $78.2 million in revenue, representing a substantial 92% year-over-year growth. This impressive performance led Ardelyx to raise its full-year 2025 revenue guidance for IBSRELA to between $270 and $275 million.</p>\n\n<p>While the company reported a net loss of $969,000 for the quarter, investors appear to be focusing on the robust revenue growth and positive outlook. Ardelyx also announced progress on its pipeline, including the development of RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas. The company plans to file an Investigational New Drug (IND) application for RDX10531 in 2026, further bolstering its future prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARDX","symbol_name":"Ardelyx","start_time":0,"source_url":"","article_id":"1189182471","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189182471","pubTimestamp":1761856579,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Ardelyx (NASDAQ: ARDX) jumped 14.37% in after-hours trading on Thursday following the release of the company's third-quarter 2025 financial results and corporate update. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARDX":"Ardelyx"},"translate_title":"个股追踪|Ardelyx盘后大涨14.37%Q3业绩强劲且指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1},"content_text":"Shares of Ardelyx (NASDAQ: ARDX) jumped 14.37% in after-hours trading on Thursday following the release of the company's third-quarter 2025 financial results and corporate update. The biopharmaceutical company reported strong revenue growth and raised its full-year guidance for its lead product, IBSRELA.\nArdelyx reported total revenue of $110.3 million for the quarter, a 12.3% increase compared to the same period last year. The company's flagship product, IBSRELA, generated $78.2 million in revenue, representing a substantial 92% year-over-year growth. This impressive performance led Ardelyx to raise its full-year 2025 revenue guidance for IBSRELA to between $270 and $275 million.\nWhile the company reported a net loss of $969,000 for the quarter, investors appear to be focusing on the robust revenue growth and positive outlook. Ardelyx also announced progress on its pipeline, including the development of RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas. The company plans to file an Investigational New Drug (IND) application for RDX10531 in 2026, further bolstering its future prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}